Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients.

Di Nisio, Marcello; van Es, Nick; Rotunno, Ludovica; Anzoletti, Nelson; Falcone, Leonardo; De Tursi, Michele; Natoli, Clara; Tinari, Nicola; Cavallo, Ilaria; Valeriani, Emanuele; Candeloro, Matteo; Guglielmi, Maria Domenica; Rutjes, Anne Wilhelmina Saskia; Porreca, Ettore (2019). Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients. Journal of thrombosis and thrombolysis, 48(1), pp. 125-133. Springer 10.1007/s11239-019-01845-6

Preview	Text DiNisio JThrombThrombolysis 2019.pdf - Published Version Available under License Publisher holds Copyright. Download (1MB) | Preview
Preview	Text DiNisio JThrombThrombolysis 2019_postprint.pdf - Accepted Version Available under License Publisher holds Copyright. Download (1MB) | Preview

The long-term performance of prediction scores for venous thromboembolism (VTE) in cancer patients has been poorly investigated. We evaluated the discriminatory performance of the Khorana, PROTECHT, CONKO, and ONKOTEV scores for the first 3-6 months and for 12 months, and re-assessed scores after 3-6 months to determine the influence of variations in patients' risk classification on performance. Retrospective cohort of ambulatory patients with active cancer who were scheduled to receive first or new line of chemotherapy. The primary outcome was symptomatic or incidental VTE. A total of 776 patients were included of whom 540 (70%) had distant metastases. The time-dependent c-statistics of Khorana, PROTECHT, CONKO, and ONKOTEV scores at 6 months were 0.61 (95% CI 0.56 to 0.66), 0.61 (95% CI 0.55 to 0.66), 0.60 (95% CI 0.54 to 0.66), and 0.59 (0.52 to 0.66), respectively, with a tendency to decrease during follow-up. None of the scores discriminated between high and low risk patients at the conventional 3-point positivity threshold. The use of a 2-point positivity threshold improved performance of all scores and captured a higher proportion of VTE. The accuracy of risk scores re-assessed at 3-6 months was modest. The Khorana, PROTECHT, CONKO, and ONKOTEV scores are not sufficiently accurate when used at a conventional threshold of 3 points. Performance improves at positivity threshold of 2 points, as evaluated in recent randomized studies on VTE prophylaxis. Score accuracy tends to decrease over time suggesting the need of periodic re-evaluation to estimate possible variation of risk.

Interest & Impact

Downloads

328 since deposited on 02 Apr 2019
64 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item